InSilico Medicine Cayman TopCo 3696
HKEX · Hong Kong SAR China · Health Technology
HKD 60.10+4.70 (+8.48%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "In-Silico Drug Discovery Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global In-Silico Drug Discovery Market to Reach US$6 Billion by 2030 The global in-silico drug discovery market was valued at US$3.3 billion in 2024 and i
As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become the latest Top Drug, underscoring the industry's momentum and commercial potential. To further advance long-acting and precise weight management, the industry has proposed a combination strategy using GIPR (glucose-dependent insulinotropic polypeptide re
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.